Iohexol Injection

Iohexol Injection is a non-ionic Contrast Media. Compared with a traditional ionic Contrast Media, Iohexol Injection has an excellent molecular structure and it can greatly improve user safety and significantly reduce adverse reactions. The iodinated contrast agenthas excellent clinical feedback and good imaging results. In 1998, Iohexol Injection was launched as Beilu's 1st iodinated Contrast Media.If you want to know iohexol injection price, please contact us.

Product name: Iohexol Injection

Generic name: Iohexol Injection

Type: Injectable Contrast Media for CT/X-ray

Ingredients: iohexol 300

Specification:

(1) 20 ml: 6 gI (2) 50 ml: 15 gI

(3) 75 ml: 22.5 gI (4) 100 ml: 30 gI

(5) 20 ml: 7 gI (6) 50 ml: 17.5 gI

(7) 100 ml: 35 gI

Administration: For injection or oral use of iodinated contrast

Adverse reactions: See the details from the package insert

Shelf life: 36 months

Indications of Iohexol Injection

The omnipaque iohexolis an X-ray contrast agent. It can be used for angiocardiography, arteriography, urography, enhanced CT examination inclduing cervical, thoracic and lumbar myelography, CT cisternography following intrathecal injection (i.e., an injection into the subarachnoid space); arthrography, endoscopic retrograde cholangiopancreatography (ERCP), herniography or fistulography, hysterosalpingography, sialography, percutaneous transhepatic cholangiography (PTC), sinography, gastroenterography, T-tube angiography, etc.

Precautions of Iohexol Injection

General precautions for the use of nonionic-monomer contrast agent:

1. iohexol contrastagents. Prophylactic medications such as steroids and H1/H2 histamine receptor antagonists may be considered for these patients.

2. oral iodinated contrastagents can provoke anaphylactoid reactions or other allergic reactions. Therefore, first aid measures should be trained in advance, and necessary rescue drugs and devices should be prepared for possible serious reactions.

Identify patients with high-risk factors.

Ensure patients are appropriately hydrated and, if necessary, the infusion may be maintained intravenously prior to examination until the contrast agent is cleared from the kidneys.

Avoid any nephrotoxic agent, oral gallbladder contrast agent, surgery for arterial occlusion, renal angioplasty or other major surgeries that increase the renal burden until the contrast agent is cleared.

Repeat radiographic testing is delayed until renal function returned to the pre-examination level.

To prevent lactic acidosis, the level of serum creatinine must be determined before intravascular injection of iodinated contrast agent into diabetic patients taking metformin. For patients with abnormal serum creatinine/renal function, metformin must be discontinued and the examinations with contrast agent must be postponed until after 48 hours of discontinuation. Metformin should be reused only after renal function and serum creatinine level are constant. In some emergency cases of patients with abnormal or unknown renal function, the physician must assess both advantages and disadvantages of using contrast agent and take precautions, such as discontinuation of metformin, adequate hydration of patients, testing of renal functions, and careful observation of symptoms of lactic acidosis.

There is a potential risk of transient hepatic dysfunction. Special attention should be paid to patients with serious hepatic and renal insufficiency due to significantly longer time to clear contrast agent. Hemodialysis patients may receive the examinations with contrast agents. Immediate hemodialysis is not necessary after the injection of contrast agent because there is no evidence showing that hemod.

Founded in 1992, Beilu Pharmais mainly engaged in the research & development, production and sales of pharmaceutical products. It is high-tech innovation company with core competence in the mri contrast mediadomestic. Beilu provides complete Contrast Media products suitable for X-Ray and Magnetic Resonance Imaging (MRI), and it is the leading manufacturer in the Contrast Media field in China.

Другие товары поставщика

	Gadopentetate Dimeglumine Injection/API	Since Gadopentetate Dimeglumine Injection was launched in 1992 by Beilu Pharma in China, it was highly recommended and accepted by the radiologist,...
	Iohexol Injection	Iohexol Injection is a non-ionic Contrast Media. Compared with a traditional ionic Contrast Media, Iohexol Injection has an excellent molecular str...
	Gadobutrol Injection/API	In 2020, Beilu launched its macrocyclic Contrast Media- Gadobutrol Injection, it is gadolinium-based non-ionic Contrast Media, a paramagnetic Contr...
	Calcobutrol	CAS No.: Molecular formula: C18H32CaN4O9 Molecular weight: 488.5461 Quality standard: CP Characteristics: White or off-white powder ...
	Iohexol Injection	Iohexol Injection is a non-ionic Contrast Media. Compared with a traditional ionic Contrast Media, Iohexol Injection has an excellent molecular str...

Все товары поставщика

Похожие товары

	Calcobutrol	Продавец: Beijing Beilu Pharmaceutical Co., Ltd	Calcobutrol CAS No.: Molecular formula: C18H32CaN4O9 Molecular weight: 488.5461 Qual...
	Repaglinide Tablets	Продавец: Beijing Beilu Pharmaceutical Co., Ltd	Repaglinide tabletsare non-sulfonylurea insulin secretion agents and are used to treat patients w...
	MRI Contrast Media	Продавец: Beijing Beilu Pharmaceutical Co., Ltd	agnetic resonance imaging Contrast Media (MRI Contrast Media), also called Magnetic resonance ima...
	Iopamidol Injection	Продавец: Beijing Beilu Pharmaceutical Co., Ltd	IopamidolInjection is the second-generation non-ionic iodinated Contrast Media launched in the gl...
	Iohexol Injection	Продавец: Beijing Beilu Pharmaceutical Co., Ltd	Iohexol Injection is a non-ionic Contrast Media. Compared with a traditional ionic Contrast Media...